Efficacy

Efficacy of Opdivo (Nivolumab) in Lung Cancer

Opdivo (Nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor that has shown significant efficacy in the treatment of lung cancer, specifically non-small cell lung cancer (NSCLC). Clinical trials have demonstrated that Opdivo can improve overall survival in patients with advanced NSCLC compared to traditional chemotherapy. In particular, the CheckMate-057 trial showed that Opdivo improved the median overall survival for patients with advanced, non-squamous NSCLC who had progressed during or after platinum-based chemotherapy. Furthermore, Opdivo has been associated with a durable response rate, meaning that some patients experience long-term control of their disease.

Opdivo's efficacy varies based on several factors, including the expression of the PD-L1 protein on tumor cells and prior treatments received by the patient. For instance, patients with higher PD-L1 expression may experience better outcomes with Opdivo. Additionally, Opdivo has been approved for use as a first-line treatment in combination with other agents, providing an option for patients with metastatic NSCLC without EGFR or ALK genomic tumor aberrations.

Efficacy of Enhertu (fam-trastuzumab deruxtecan-nxki) in Lung Cancer

Enhertu (fam-trastuzumab deruxtecan-nxki) is an antibody-drug conjugate that targets HER2, a protein overexpressed in a subset of NSCLC tumors. The efficacy of Enhertu in lung cancer has been evaluated in patients with HER2-mutant unresectable and/or metastatic NSCLC who have received prior systemic therapy. Clinical trials, such as the DESTINY-Lung01 trial, have shown promising results, with a notable objective response rate and median progression-free survival in this patient population. The responses observed with Enhertu have been both deep and durable, indicating a significant clinical benefit for patients with HER2-mutant NSCLC.

Enhertu's efficacy in lung cancer highlights the importance of molecular profiling in NSCLC to identify patients who may benefit from targeted therapies. As HER2 mutations are present in a small percentage of NSCLC cases, Enhertu provides a tailored treatment option for this group of patients. The development and approval of Enhertu for HER2-mutant NSCLC represent a step forward in personalized medicine, offering a new line of therapy for patients who have historically had limited treatment options.